StockNow
Log in
U.S. Markets

Biogen (BIIB) says Phase 2 CELIA data presented at AAIC demonstrate meaningful clinical outcomes and robust tau reduction with diranersen in early Alzheimer’s disease

StockNow breaking-news AI analysis

Biogen is advancing diranersen to registrational development based on robust tau reduction in Phase 2 CELIA data, despite missing the primary dose-response endpoint. Market sentiment remains cautiously optimistic.

1 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
U.S. Markets

Eli Lilly (LLY) Q2 2026 (USD): Adj. EPS 8.38 (exp. 6.01), Revenue 23bln (exp. 20.7bln)

LLYGeopolitics

Gulf official tells CNN “50:50” chance US and Iran could reach deal by Friday, CNN reports; Iranian delegation does not include IRGC, which would need to sign off on details of provisional agreement

U.S. Economy

US ADP Employment Change (Jul) 44K vs. Exp. 70K (Prev. 98K)